Last reviewed · How we verify
GTX-102 high dose fast Period 1 and Period 2
GTX-102 high dose fast Period 1 and Period 2 is a Small molecule drug developed by Grace Therapeutics Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | GTX-102 high dose fast Period 1 and Period 2 |
|---|---|
| Sponsor | Grace Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GTX-102 high dose fast Period 1 and Period 2 CI brief — competitive landscape report
- GTX-102 high dose fast Period 1 and Period 2 updates RSS · CI watch RSS
- Grace Therapeutics Inc. portfolio CI
Frequently asked questions about GTX-102 high dose fast Period 1 and Period 2
What is GTX-102 high dose fast Period 1 and Period 2?
GTX-102 high dose fast Period 1 and Period 2 is a Small molecule drug developed by Grace Therapeutics Inc..
Who makes GTX-102 high dose fast Period 1 and Period 2?
GTX-102 high dose fast Period 1 and Period 2 is developed by Grace Therapeutics Inc. (see full Grace Therapeutics Inc. pipeline at /company/grace-therapeutics-inc).
What development phase is GTX-102 high dose fast Period 1 and Period 2 in?
GTX-102 high dose fast Period 1 and Period 2 is in Phase 1.